View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 29, 2018

Campaigners warn stockpiling medicines for a no-deal Brexit could cost £2bn

Anti-Brexit campaign group Best for Britain has cautioned that the UK Secretary of State for Health and Social Care Matt Hancock’s plan for six weeks of medicines to be stockpiled in the event of a no-deal Brexit could cost up to £2bn

By Allie Nawrat

Anti-Brexit campaign group Best for Britain has cautioned that the UK Secretary of State for Health and Social Care Matt Hancock’s plan for six weeks of medicines to be stockpiled in the event of a no-deal Brexit could cost up to £2bn.

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

It is currently unclear who would be responsible for this bill.

This price of stockpiling medicines for a no-deal Brexit is based upon data from a report published by healthcare think tank King’s Fund in April this year, which estimated that the total spent by the NHS on medicines in 2016-17 was $17.4bn.

Best for Britain supporter and Labour MP Owen Smith said: “I don’t remember anyone warning that Brexit would mean we’d have stockpile drugs or this would cost the NHS and taxpayers up to £2bn. Maybe they should have slapped that on the side of the bus. Every day it seems as though there is another hidden cost being revealed.”

Hancock announced the government’s strategy for stockpiling medicines for a no-deal Brexit in a letter addressed to pharmaceutical companies. As well as calling on them to increase their stock of medicines by at least six weeks on top of their existing buffer stocks, the companies were asked to ensure they had plans to air freight products with a short shelf life into the UK.

The Health Secretary also sent a letter to NHS organisations in which he urged GPs, pharmacists and other healthcare professionals to not start stockpiling medicines for a no-deal Brexit and instead rely on pharmaceutical companies.

Hancock wrote: “Local stockpiling is not necessary and any incidences involving the over ordering of medicines will be investigated and followed up with the relevant Chief or Responsible Pharmacist directly.

“Clinicians should advise patients that the government has plans in place to ensure a continued supply of medicines to patients from the moment we leave the EU. Patients will not need to and should not seek to store additional medicines at home.”

Related Companies

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology